Advanced search
Publication Cover
Journal of Medical Economics Volume 16, 2013 - Issue 1
Submit an article Journal homepage
1,059
Views
16
CrossRef citations to date
0
Altmetric
Original Article

A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom

Lisa BernardCornerstone Research Group Inc. Burlington, ONCanadaCorrespondence[email protected]
,
David MendelssohnHumber River Regional Hospital Weston, ONCanada
,
Elizabeth DunnGenzyme Corporation Cambridge, MAUSA
,
Colin HutchisonUniversity of Birmingham and University Hospital Birmingham Edgbaston, BirminghamUK
&
Daniel T GrimaCornerstone Research Group Inc. Burlington, ONCanada
Pages 1-9 | Accepted 25 Jul 2012, Published online: 10 Sep 2012

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Panagiotis Petrou. (2019) A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia. Expert Review of Pharmacoeconomics & Outcomes Research 19:3, pages 287-298.
Read now
Shahrzad Ossareh. (2014) Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients. International Journal of Nephrology and Renovascular Disease 7, pages 161-168.
Read now
Sushant Ramdas Taksande & Elaine M Worcester. (2014) Calcium supplementation in chronic kidney disease. Expert Opinion on Drug Safety 13:9, pages 1175-1185.
Read now

Articles from other publishers (13)

Kamolpat Chaiyakittisopon, Oraluck Pattanaprateep, Narisa Ruenroengbun, Tunlanut Sapankaew, Atiporn Ingsathit, Gareth J. Mckay, John Attia & Ammarin Thakkinstian. (2021) Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations. The European Journal of Health Economics 22:4, pages 571-584.
Crossref
Steven Habbous, Sebastian Przech, Janet Martin, Amit X. Garg & Sisira Sarma. (2018) Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease. Value in Health 21:3, pages 318-325.
Crossref
Jang-Hee Cho, Hye Min Jang, Hee-Yeon Jung, Ji-Young Choi, Sun-Hee Park, Chan-Duck Kim, Chul Woo Yang, Dong-Chan Jin & Yong-Lim Kim. (2018) A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients. Clinical Therapeutics 40:1, pages 123-134.
Crossref
Li Yang, Seng Chuen Tan, Can Chen, Xingzhi Wang, Xinya Li & Xiaoyan Yang. (2016) Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China. Clinical Therapeutics 38:11, pages 2459-2467.e1.
Crossref
Rana Rizk, Mickaël Hiligsmann, Mirey Karavetian & Silvia MAA Evers. (2016) Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review. Nephrology 21:3, pages 178-187.
Crossref
Vasily Belozeroff, Glenn M. Chertow, Christopher N. Graham, Bastian Dehmel, Patrick S. Parfrey & Andrew H. Briggs. (2015) Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. Value in Health 18:8, pages 1079-1087.
Crossref
Florian S. Gutzwiller, Alena M. Pfeil, Zanfina Ademi, Patricia R. Blank, Peter G. Braunhofer, Thomas D. Szucs & Matthias Schwenkglenks. (2015) Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland. PharmacoEconomics 33:12, pages 1311-1324.
Crossref
Matteo Ruggeri, Antonio Bellasi, Filippo Cipriani, Donald Molony, Cynthia Bell, Domenico Russo & Biagio Di Iorio. (2014) Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. Journal of Nephrology 28:5, pages 593-602.
Crossref
Caroline M. Perry & Greg L. Plosker. (2014) Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease. Drugs 74:7, pages 771-792.
Crossref
Shunsuke Goto, Hirotaka Komaba, Masafumi Fukagawa & Shinichi Nishi. (2013) Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder. Kidney International Supplements 3:5, pages 457-461.
Crossref
Adrian Covic & Luminita Voroneanu. (2013) Epic battles in the phosphate-binder wars—the last episode?. Nature Reviews Nephrology 9:9, pages 497-498.
Crossref
Fabio Malberti. (2013) Hyperphosphataemia: Treatment Options. Drugs 73:7, pages 673-688.
Crossref
Dale C. Hesdorffer & Charles E. Begley. (2013) Surveillance of epilepsy and prevention of epilepsy and its sequelae. Current Opinion in Neurology 26:2, pages 168-173.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.